Budget Impact Analysis of the Introduction of Subcutaneous Infliximab (CT-P13 SC) for the Treatment of Rheumatoid Arthritis in the United Kingdom.
Taeksang KwonMinyoung JangHyun Kyeong YooJames PotterTaek Sang KwonPublished in: Applied health economics and health policy (2021)
Use of CT-P13 SC may lead to substantial cost savings for the UK society.